Radiolabeled recombinant murine B-cellstimulatory factor 1 (BSF-1) was used to characterize receptors specific for this lymphokine on the surface of primary B and T cells and in vitro cell lines representing the B-cell, T-cell, mast cell, macrophage, and myelomonocytic lineages. BSF-1 binding was rapid and saturable at 40C and 370C with a slow dissociation rate. On all cell types examined, BSF-1 bound to a single class of high-affinity receptor (<2000 receptors per cell) with a Ka of 101o-101I M-'. Receptor expression on resting primary B and T cells was low (<100 receptors per cell), whereas activation with lipopolysaccharide or Con A produced a 5-to 10-fold increase in receptor numbers. Among a panel of lymphokines and growth hormones, only unlabeled BSF-1 was able to compete for the binding of 1HI-labeled BSF-1. Affinity crosslinking experiments resulted in the identification on all cells tested of a receptor protein with an average Mr of 75,000.
B-cell-stimulating factor 1 (BSF-1), also known as interleukin 4 (IL-4; ref. 1 ) and B-cell growth factor (2), was originally defined by its ability to facilitate the proliferative response of B cells to low concentrations of antibodies directed to surface immunoglobulin (3) . More recently, purified BSF-1 has been found to stimulate the proliferation of several IL-2-and IL-3-dependent cell lines (4) (5) (6) , to induce the expression of class II major histocompatibility complex molecules on resting B cells (7, 8) , and to enhance the secretion of IgE and IgG1 by stimulated B cells (9, 10) . These results suggest that BSF-1 is a growth factor and a differentiation factor and that it has effects on cell lineages (T-cell and hematopoietic) outside the B-lymphocyte compartment.
With the recent cloning and expression of the gene encoding murine BSF-1 (1, 5) , it has been demonstrated conclusively that these multiple activities are mediated by a single molecule. In addition, the availability of purified recombinant BSF-1 has made it possible to undertake a search for specific receptors for this molecule on the plasma membrane of responding cells. This paper describes the use of recombinant murine BSF-1, radiolabeled with 1251I to high specific activity, to study the cellular distribution of the BSF-1 receptor as well as provide kinetic and structural characterization of the receptor. This initial characterization of the receptor for murine BSF-1 will lay the groundwork that will be necessary to fully understand how this single lymphokine, interacting with its receptor on cells of different lineages, may mediate such a diverse array of biological activities.
MATERIALS AND METHODS
Cell Preparations. FDC-P2, an IL-3-dependent murine bone marrow-derived line (11) , and CTLL-2, an IL-2-dependent murine T-cell line (12), were maintained as described (4) . 32D/IL-3 cells, which were developed from the IL-3-dependent 32Dcl-23 cell line (13) , and FD.C/2 cells, which were developed from the IL-3-dependent FDC-P2 cell line, were kindly provided by James Watson (Auckland Medical School, Auckland, New Zealand). In addition to expressing IL-3 receptors, these cell lines have also been induced to express IL-2 receptors by culture in human IL-2 and were maintained as described (14, 15) . All other cells listed in Table  1 were grown in RPMI 1640 medium containing 5-10% fetal bovine serum and antibiotics with or without 5 nM 2-mercaptoethanol and 1% sodium pyruvate.
B-and T-cell populations were each purified from spleens of female C57BL/6J mice 8-12 weeks of age (The Jackson Laboratory). B cells were purified as described (4) and were stimulated by culturing in RPMI 1640 medium containing 5% fetal bovine serum, penicillin, streptomycin, glutamine, 0.05 mM 2-mercaptoethanol, and 10 ,ug of lipopolysaccharide per ml at 2 x 106 cells per ml.
Splenic T cells were purified by using nylon wool as described (16) and were activated by culturing for 2 days in 16-mm wells at 2 x 106 cells per well in the presence of irradiated [3000 rads (1 rad = 0.01 gray)] unfractionated syngeneic spleen cells (2 x 106 cells per well) in RPMI 1640 medium containing 10% fetal bovine serum, 0.05 mM 2-mercaptoethanol, and 2.5 ptg of Con A per ml. Activated T cells were harvested and dead cells were removed by discontinuous density gradient centrifugation over metrizamide.
Thymocytes were induced by culturing 5 x 106 cells per ml in RPMI 1640 medium, 10% fetal bovine serum, 0.05 mM 2-mercaptoethanol, and 2.5 ,g of Con A per ml for 2 days. Activated thymocytes were harvested and dead cells were removed by discontinuous density gradient centrifugation on metrizamide.
Hormone Preparations. Human recombinant IL-2 was expressed in yeast under the control of the alcohol dehydrogenase 2 promoter, purified from the yeast medium to homogeneity by reversed-phase HPLC according to methods previously described (V. Price and D.L.U., unpublished data, refs. [17] [18] [19] , and radiolabeled (20) . IL-3 (CSF-2a), recombinant murine granulocyte/macrophage colony-stimulating factor (GM-CSF), and recombinant human IL-la and IL-1f3 were obtained as described (18, 21, 22) . Nerve growth factor, fibroblast growth factor, platelet-derived growth factor, and epidermal growth factor were obtained from Bethesda Research Laboratories. Human follicle-stimulating hormone, human luteinizing hormone, human thyroid-stimulating hormone, human growth hormone, and bovine insulin were obtained from Calbiochem-Behring.
Recombinant Murine BSF-1 Purifilcation and Radiolabeling. Complementary DNA encoding murine BSF-1 was cloned from a cDNA library that had been prepared from sized mRNA isolated from EL-4 thymoma cells previously stimu-lated with phorbol 12-myristate 13-acetate. The BSF-1 cDNA was inserted into a plasmid where its transcription, translation, and secretion were under the control of the ADH2 promoter and a factor leader sequences. As a result, yeast transformed with this plasmid secreted murine BSF-1 into the yeast culture broth. Purification of BSF-1 was achieved by five sequential reversed-phase HPLC steps on C4 and C18 derivatized silica (Vydac, separations group) with gradients of acetonitrile containing 0.1% trifluoroacetic acid or 1-propanol (60% 1-propanol in 0.9 M acetic acid/pyridine to pH 4.5) as described for the purification of other lymphokines (17) (18) (19) . Following purification, BSF-1 concentrations were determined by fluorescamine analysis (23) of the purified protein with bovine serum albumin as a standard. BSF-1 activity was measured in either a B-cell or an FDC-P2 proliferation assay as described (4) . The specific activity of purified recombinant murine BSF-1 was determined to be 2 x 105 units/pg.
Murine recombinant BSF-1 was radiolabeled by using the Enzymobead radioiodination reagent (Bio-Rad) essentially as described for murine recombinant GM-CSF (21) . The specific activity of radiolabeled BSF-1 preparations was estimated to be 0.5-2.0 x 1016 cpm/mmol based on a Mr of 49,000 and on a recovery of 40% from control experiments in which an aliquot of BSF-1 was spiked with 125I-labeled BSF-1 (125I-BSF-1) and put through the iodination protocol, with omission of 125I. Bioactivity of 125I-BSF-1 was determined in a B-cell proliferation assay (4) .
Assay for Binding of 12SI-BSF-1 to Intact Cells. Binding assays (24) were performed essentially as described for murine 125I-labeled GM-CSF (21) . Sodium azide (0.2%) was included in all binding assays to inhibit internalization and degradation of '25I-BSF-1 by cells at 37°C. Association and dissociation kinetic experiments were conducted as described (21).
Crosslinking to Intact Cells. Crosslinking experiments were performed essentially as described (21) . Briefly, cells (4 x 107 per ml) were incubated with 125I-BSF-1 (1.2 x 10-1o M) at 40C
in the presence and absence of a 50-fold or greater molar excess of unlabeled BSF-1 for 2 hr. The cells were then washed and bis(sulfosuccinimidyl)suberate was added to a final concentration of 0.1 mg/ml. After 30 min at 25°C, the cells were washed and resuspended in 100 ,ul of phosphatebuffered saline (PBS)/1% Triton containing 2 mM phenylmethylsulfonyl fluoride, 10 ,M pepstatin, 10 ,uM leupeptin, 2 mM o-phenanthroline, and 2 mM EGTA to prevent proteolysis. Aliquots of the extract supernatants were analyzed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (NaDodSO4/PAGE) (25) .
Data Analysis. Curve fitting of binding and kinetic data was done by using RS/1 (Bolt, Beranek, and Newman, Boston), a commercially available data processing package running on a VAX 11/750 under the VMS operating system, and kinetic data were analyzed as described (21) .
RESULTS
Recombinant murine BSF-1 was purified to homogeneity by reversed-phase HPLC and iodinated to high specific activity (in the range of 1 x 1016 cpm/mmol). Such preparations were stable for at least 2 weeks when stored at 4°C in 0.05 M NaPO4 (pH 7.2) containing 0.01% bovine serum albumin and 0.02% sodium azide and retained 100% of their biological activity (data not shown).
Recombinant murine 125I-BSF-1 was shown to exhibit specific binding to the factor-dependent bone marrow-derived cell line FDC-P2. Preliminary experiments indicated that binding was saturable and required -60 min to reach equilibrium at either 37°C or 4°C, with the rate of approach to equilibrium being only slightly slower at 4°C (data not shown). A low level of nonspecific binding of 1251-BSF-1 was seen that remained constant over the time course. Fig. 1A shows the association kinetics at 37°C of 125I-BSF-1 with FDC-P2 at three different concentrations of ligand. The data show that the final equilibrium amount bound to cells and the rate of approach to equilibrium are dependent on the initial concentration of 1251-BSF-1 in the medium. The curves passing through the data are best-fit single exponential time-dependency curves (26) , consistent with the presence of a single population of receptors on these cells. The Inset (Fig.  1B) shows the dependence of the pseudo first-order forward rate constant (determined by curve fitting the data of Fig. 1A) on the concentration of 125I-BSF-1 in the medium. For a bimolecular reaction such data should fit a straight line, with the slope being the forward rate constant and the intercept on the ordinate being the reverse rate constant (26) M; e, human IL-1/3, 5 x 10-7 M; f, CSF-2a (IL-3), 7.5 x 10-9 M; g, recombinant murine GM-CSF, 7.5 x 10-7 M; h, epidermal growth factor, 3 ug/ml; i, fibroblast growth factor, 1 Ag/ml; j, nerve growth factor, 2 ,ug/ml; k, insulin, 1.1 x 10-' M; 1, luteinizing hormone (human), 1 ,g/ml; m, growth hormone (human), 1.7 x 10-7 M; n, thyroid-stimulating hormone, 1 ,ug/ml; o, follicle-stimulating hormone, 1 jig/ml; p, anti-LFA-1 (M17/5.2), 15 ,ug/ml. Concentrations of partially pure hormone preparations are given in jLg/ml of total protein. Incubation was for 1 hr at 370C and binding was assayed.
Data are expressed as ±SEM.
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Proc. Natl. Acad. Sci. USA 84 (1987) did BSF-1 inhibit binding of 'l25-labeled IL-2 to these cells (data not shown). In addition, an anti-LFA-1 monoclonal antibody, M17/5.2 (Hybritech, La Jolla, CA) directed against the a chain of LFA-1, did not inhibit 1251I-BSF-1 binding even at a concentration of 15 gg/ml (Fig. 3, column p) .
A number of primary cells and continuous cell lines of murine origin were examined for their ability to bind 1251I BSF-1 (Table 1) . In all cases, complete binding curves were done over a range of 125I-BSF-1 concentrations and receptor numbers per cell were generated by Scatchard analysis of the data. The high-affinity constant of BSF-1 binding, combined with the very high specific activity of the radiolabeled molecule, allowed receptor levels of <100 per cell to be reproducibly measured. The number of receptors is particularly low on resting B and T cells but these populations appear to increase their receptor numbers by 5-to 10-fold upon stimulation with lipopolysaccharide or Con A (Table 1) . Although all of the murine lines tested displayed BSF-1 receptors, neither a human B lymphoma (RPMI-1788) nor a human T lymphoma (CEM) bound any murine I251-BSF-1.
Further characterization of the BSF-1 receptor on five of these cell lines, FDC-P2, CTLL, 32D, P815, and BCL-1, was carried out by affinity crosslinking. Fig. 4 (1987) 1673 higher than that required to produce biological effects, reminiscent of many other systems, including GM-CSF (21), IL-3 (28), and IL-1 (29) , in which only fractional receptor occupancy is required to produce a maximal biological effect. As has been described (21), these three factors and BSF-1 also share a common pattern of ligand dissociation, in which a slowly exchanging component was observed that might reflect a subpopulation of receptors that can effectively bind ligand irreversibly and perhaps mediate a biological effect through this interaction even at extremely low levels of receptor expression. It is interesting to note in this light that activation of B and T cells with lipopolysaccharide and Con A, respectively, which enhances the responsiveness of these cells to BSF-1, also apparently increases the number of receptors expressed on these cells 5-to 10-fold.
Kinetic characterization of BSF-1 binding to FDC-P2 and CTLL cells revealed no obvious differences between the receptors found on these cells. Preliminary structural information on the BSF-1 receptor, provided by affinity crosslinking experiments, substantiated the similarity. Both cell types exhibited a crosslinked species having an average Mr of 124,000, which would correspond to a receptor size of Mr 75,000. A similar size receptor protein was also found on the 32D, P815, and BCL-1 cell lines. The size of the BSF-1 receptor and the failure of an anti-LFA-1 antibody to inhibit binding of BSF-1 to cells suggest that the receptor is not directly related to LFA-1, as has been suggested (36). This does not rule out the possibility, however, that LFA-1 could be associated with a BSF-1 receptor binding protein in the plasma membrane. It was also clear from inhibition studies that BSF-1 does not share a common receptor with either IL-2 or IL-3 nor do these molecules appear to compete with each other in any direct way for specific receptor binding. This point is ofinterest due to the ability of BSF-1 to stimulate the proliferation of several IL-2-and IL-3-dependent cell lines, in a manner similar to IL-2 and IL-3 themselves.
These studies have shown that though BSF-1 is capable of binding to a wide range of cell types, the receptor protein with which this molecule interacts exhibits no overt differences between cells of different lineages. The level of receptor expression, however, can be modulated at least on primary B and T cells by activation with mitogenic agents. It is hoped that further study on the distribution of the BSF-1 receptor, the conditions under which its expression is altered, and its possible interaction with other lymphokine receptors will produce some clues to explain the diverse array of activities associated with BSF-1.
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